These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Analysis of recombinant human interleukin-11 fusion protein derived from Escherichia coli lysate by combined size-exclusion and reversed-phase liquid chromatography.
    Author: Amari JV, Mazsaroff I.
    Journal: J Chromatogr A; 1996 Apr 05; 729(1-2):113-24. PubMed ID: 9004932.
    Abstract:
    A two-dimensional size-exclusion-reversed-phase high-performance liquid chromatographic assay has been developed for the quantitation of recombinant human interleukin-11 fusion protein (rhIL-11 FP) expressed in E. coli cells. The sample preparation procedure included the optimization of lysis buffer components to achieve maximum rhIL-11 FP recovery through the disruption of associations between rhIL-11 FP and E. coli components. The E. coli cells were dialyzed into lysis buffer and lysed by a French Press prior to two-dimensional chromatographic analysis. A size-exclusion column was used first to remove high- and low-molecular-mass E. coli components. Then reversed-phase chromatography was used to separate and quantify the rhIL-11 FP. The assay was linear over the range of 0.0294 to 0.235 mg/ml. The limit of quantitation, 0.0294 mg/ml, was based on % normalized residuals and precision criteria not exceeding 10%. The reproducibility of the assay for lysate samples was good on a daily (% R.S.D. = 1.0; n = 5) and a day-to-day reproducibility was good (% R.S.D. = 2.2; n = 9). Selectivity and chromatographic peak identification were based upon gel electrophoresis and N-terminal sequencing of the rhIL-11 FP peak collected from the reversed-phase column.
    [Abstract] [Full Text] [Related] [New Search]